Patiromer

(Veltassa®)

Patiromer

Drug updated on 11/10/2023

Dosage FormSuspension (oral; 8.4 g, 16.8 g, 25.2 g)
Drug ClassPotassium binders
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Veltassa (patiromer) Prescribing Information.2021FDA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Safety and efficacy of new potassium binders on hyperkalemia management in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials.2023Clinical Research in Cardiology
Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical Trials2023American journal of kidney diseases
The Efficacy and Safety of Patiromer for Heart Failure Patients: A Systematic Review and Meta-Analysis2023Cardiovascular drugs and therapy
Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis2023European journal of internal medicine
Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia2022European journal of pharmacology
Safety and Efficacy of Patiromer in Hyperkalemic Patients with CKD: A Pooled Analysis of Three Randomized Trials2022Kidney360
Clinical and Pharmacoeconomic combined report patiromer (Veltassa).2021CADTH
Patiromer and sodium zirconium cyclosilicate in treatment of hyperkalemia: a systematic review and meta-analysis.2021Current Therapeutic Research, Clinical and Experimental
Binding potassium to improve treatment with renin-angiotensin-aldosterone system inhibitors: results from multiple one-stage pairwise and network meta-analyses of clinical trials.2021Frontiers in Medicine
Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis2021Journal of clinical medicine
Patiromer for treating hyperkalaemia.2020NICE
Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. 2020Cochrane Database of Systematic Reviews
Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials2020Progress in cardiovascular diseases
Efficacy and safety of the pharmacotherapy used in the management of hyperkalemia: a systematic review.2019Pharmacy Practice
Evidence in support of hyperkalaemia management strategies: A systematic literature review.2018The International Journal of Clinical Practice

Clinical Practice Guidelines

Document TitleYearSource
Clinical Practice Guidelines: treatment of acute hyperkalaemia in adults.2020The Renal Association